Natco Pharma bags USFDA approval for anti-ulcer drug

The approval is a green signal for the pharma company to market the product in the US.

 

New Delhi, December 19, 2012: Natco Pharma has received the approval from the US regulator, Food and Drug Administration (FDA) to market the anti-ulcer drug, Lansoprazole delayed release capsules in the US market.

 

The company said in a BSE filing today that it has received the approval from USFDA for Lansoprazole delayed release capsules in the strengths of 15 mg and 30 mg. The company also added that the shipments of the products will start on an immediate basis.

 

It is worth noting here that the share price of Natco Pharma touched a 52-week high before ending at Rs 490.25 on the Bombay Stock Exchange (BSE), up 4.89 per cent as compared to its previous close.

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...